October 4, 2017 06:59 AM EDT

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

John Carroll

Editor & Founder

A couple of years ago, GSK’s venture arm SR One brought in Jim Broderick as its first-ever entrepreneur-in-residence. And today, they’re backing his new cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

John Carroll

Editor & Founder

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Backed by Big Phar­ma VCs, Palleon ramps up a new ap­proach to im­muno-on­col­o­gy with a $48M start­up round

John Carroll

Editor & Founder

Sign up to read this article for free.

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence